Platelet-Rich Plasma for Treating Androgenic Alopecia: A Systematic Review
Platelet-rich plasma (PRP) contains a variety of growth factors and proteins that can accelerate tissue repair. Androgenic alopecia is a genetic disorder characterized by atrophy of hair follicles and hair loss. At present, PRP injections for hair restoration have become a popular though controversial practice. We conducted a meta-analysis to compare the differences between patients treated with local injections of PRP and control group subjects to explore the effectiveness of PRP treatment for androgenic alopecia.
Materials and Methods
We searched PubMed, EMBASE and the Cochrane Library until Jan 2019 for human studies evaluating the efficacy of PRP for the treatment of androgenic alopecia.
We retrieved 132 papers; 11 articles matched our inclusion criteria and comprised 262 androgenic alopecia patients. Through a meta-analysis, we found a significantly locally increased hair number per cm2 after PRP injections in the treatment group versus the control group (mean difference 38.75, 95% CI 22.22–55.28, P < .00001). Similarly, a significantly increased terminal hair density was found in the PRP group compared with the control group (mean difference 22.83, 95% CI 0.28–45.38, P = 0.05).
Most studies suggest that subcutaneous injection of PRP is likely to reduce hair loss, increase hair diameter and density in patients with androgenic alopecia. Because of the low quality of the studies, small sample sizes, different treatment regimens and possible publication bias, the results of this meta-analysis should be interpreted with caution. Furthermore, more randomized controlled studies should be performed.
Level of Evidence III
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
KeywordsAndrogenic alopecia Platelet-rich plasma Meta-analysis
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflicts of interest to disclose.
Human and Animal Rights
This article does not contain any studies with human participants or animals performed by any of the authors.
For this type of study informed consent is not required.
- 8.Abaroa F, Reyes K, Barrera D, Castelan E, Montemayor B, Izabal G, Perez I, Moreno A (2016) Histological findings of follicular units in patients with androgenetic alopecia before and after application of autologous platelet-rich plasma. Dermatologia Revista Mexicana 62:97–105Google Scholar
- 12.Gentile P, Cole JP, Cole MA, Garcovich S, Bielli A, Scioli MG, Orlandi A, Insalaco C, Cervelli V (2017) Evaluation of not-activated and activated PRP in hair loss treatment: role of growth factor and cytokine concentrations obtained by different collection systems. Int J Mol Sci 18:408CrossRefGoogle Scholar
- 15.Rodrigues BL, Montalvao SAL, Cancela RBB, Silva FAR, Urban A, Huber SC, Junior J, Lana J, Annichinno-Bizzacchi JM (2019) Treatment of male pattern alopecia with platelet-rich plasma: a double-blind controlled study with analysis of platelet number and growth factor levels. J Am Acad Dermatol 80:694–700CrossRefGoogle Scholar
- 24.Farid CI, Abdelmaksoud RA (2016) Platelet-rich plasma microneedling versus 5% topical minoxidil in the treatment of patterned hair loss. J Egypt Women’s Dermatol Soc. https://doi.org/10.1097/01.ewx.0000472824.29209.a8 Google Scholar
- 25.Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, Spuls PI, Trakatelli M, Finner A, Kiesewetter F, Trueb R, Rzany B, Blume-Peytavi U (2011) Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Deutsch Dermatol Ges 9(Suppl 6):S1–57Google Scholar